US Edition
PSMA-PET Imaging Product, Gozellix, Launches on US Market
Summary by urologytimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Telix Launches New Prostate Cancer Imaging Agent, Gozellix®, in U.S.
Telix Launches New Prostate Cancer Imaging Agent, Gozellix®, in U.S. Melbourne (Australia) and Indianapolis, IN (U.S.) | 11 June 2025 Telix today announces that its next-generation PSMA-PET imaging[1] agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United States (U.S.). Gozellix is available through Telix’s comprehensive network of distri…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
